VIPoma other imaging findings
Jump to navigation
Jump to search
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma other imaging findings On the Web |
|
American Roentgen Ray Society Images of VIPoma other imaging findings |
|
Risk calculators and risk factors for VIPoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]
Overview
Other imaging studies for VIPoma include somatostatin receptor scintigraphy and PET scan using radiolabeled somatostatin analogs.
Other Imaging Findings
- Somatostatin receptor scintigraphy (Octreoscan) is used to localize the tumor, which is usually metastatic at presentation.[1][2][3]
- Functional PET scan is also used to diagnose somatostatin receptor positive neuroendocrine tumors.
- Nearly 80-90% of all VIPoma are somatostatin receptor positive.
References
- ↑ Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T (2014). "Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male". Hematol Oncol Stem Cell Ther. 7 (3): 109–15. doi:10.1016/j.hemonc.2014.03.002. PMID 24785507.
- ↑ Müller, Sven; Kupka, Susan; Königsrainer, Ingmar; Northoff, Hinnak; Sotlar, Karl; Bock, Thomas; Kandolf, Reinhard; Traub, Frank; Königsrainer, Alfred; Zieker, Derek (2012). "MSH2 and CXCR4 involvement in malignant VIPoma". World Journal of Surgical Oncology. 10 (1): 264. doi:10.1186/1477-7819-10-264. ISSN 1477-7819.
- ↑ Virgolini, I.; Patri, P.; Novotny, C.; Traub, T.; Leimer, M.; Fuger, B.; Li, S. R.; Angelberger, P.; Raderer, M.; Wogritsch, S.; Kurtaran, A.; Kletter, K.; Dudczak, R. (2001). "Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy". Annals of Oncology. 12 (suppl 2): S41–S45. doi:10.1093/annonc/12.suppl_2.S41. ISSN 0923-7534.